拉姆达Lambda重要突变位点研究 | ||
货号 | 分子, 标签 | 突变位点 |
40588-V07E31 | N, His | P13L、R203K、G204R、G214C |
40592-V08H113 | RBD, His | L452Q、F490S |
40589-V08B23(开发中) | S1+S2 ECD, His | G75V、T76I、R246N、Δ247、Δ253、L452Q、F490S、D614G、T859N |
40589-V08B24 (开发中) | S1+S2 ECD, His | G75V、T76I、R246del、S247del、Y248del、L249del、T250del、P251del、G252del、D253N、L452Q、F490S、D614G、T859N |
40591-V08H31 (开发中) | S1, His | G75V、T76I、R246N、Δ247、Δ253、L452Q、F490S、D614G |
40592-V49H6-B (开发中) | RBD, His & AVI | L452Q、F490S |
德尔塔Delta及Delta plus重要突变位点研究 | ||
货号 | 分子, 标签 | 突变位点 |
40588-V07E32 | N, His | D63G、R203M、G215C、D377Y |
40592-V08H115 | RBD, His | K417N、L452R、T478K |
40592-V49H5-B | RBD, His & AVI | K417N、L452R、T478K |
40589-V08B25 (开发中) | S1+S2 ECD, His | T19R、G142D、W258L、K417N、L452R、T478KD614G、D950N、P681R |
40589-V08B26 (开发中) | S1+S2 ECD, His | T19R、V70F、E156G、del157/158、A222V、K417N、L452R、T478K、D614G、P681R、D950N |
40589-V08B27 (开发中) | S1+S2 ECD, His | T19R、E156G、del157/158、L452R、T478K、D614G、P681R、D950N |
End
参考资料:
[1]Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
[2]SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance.
往期精选
围观
热文
热文
热文
热文
免疫疗法 | 生物仿制药 | 疫苗 | 耐药性 | 药物靶点 | 健康生活 | 药企新闻 | 药物盘点 | 制药技术 | 药物副作用